PT1898904E - Formulação de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]--pirrolidina-2(s)-carbonitrilo de libertação modificada - Google Patents
Formulação de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]--pirrolidina-2(s)-carbonitrilo de libertação modificada Download PDFInfo
- Publication number
- PT1898904E PT1898904E PT06772653T PT06772653T PT1898904E PT 1898904 E PT1898904 E PT 1898904E PT 06772653 T PT06772653 T PT 06772653T PT 06772653 T PT06772653 T PT 06772653T PT 1898904 E PT1898904 E PT 1898904E
- Authority
- PT
- Portugal
- Prior art keywords
- adamant
- ylamino
- pyrrolidine
- acetyl
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68971905P | 2005-06-10 | 2005-06-10 | |
US69030905P | 2005-06-14 | 2005-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1898904E true PT1898904E (pt) | 2009-12-23 |
Family
ID=37532821
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT06772653T PT1898904E (pt) | 2005-06-10 | 2006-06-08 | Formulação de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]--pirrolidina-2(s)-carbonitrilo de libertação modificada |
PT09172285T PT2191824E (pt) | 2005-06-10 | 2006-06-08 | Formulação de libertação modificada de 1-[(3-hidroxiadamant- 1-ilamino)-acetil]-pirrolidina-2(s)-carbonitrilo |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT09172285T PT2191824E (pt) | 2005-06-10 | 2006-06-08 | Formulação de libertação modificada de 1-[(3-hidroxiadamant- 1-ilamino)-acetil]-pirrolidina-2(s)-carbonitrilo |
Country Status (33)
Country | Link |
---|---|
US (2) | US20100021539A1 (pt) |
EP (2) | EP1898904B1 (pt) |
JP (7) | JP5579986B2 (pt) |
KR (1) | KR101312812B1 (pt) |
AR (1) | AR054383A1 (pt) |
AT (2) | ATE549019T1 (pt) |
AU (1) | AU2006257947B2 (pt) |
BR (1) | BRPI0613499B8 (pt) |
CA (1) | CA2610422A1 (pt) |
CY (1) | CY1109719T1 (pt) |
DE (1) | DE602006009656D1 (pt) |
DK (1) | DK1898904T3 (pt) |
EC (1) | ECSP077987A (pt) |
ES (2) | ES2334261T3 (pt) |
GT (1) | GT200600246A (pt) |
HK (2) | HK1117037A1 (pt) |
HR (1) | HRP20090680T1 (pt) |
IL (1) | IL187420A (pt) |
JO (1) | JO2584B1 (pt) |
MA (1) | MA29564B1 (pt) |
MX (1) | MX2007015677A (pt) |
MY (1) | MY152185A (pt) |
NO (1) | NO343043B1 (pt) |
NZ (1) | NZ563447A (pt) |
PE (3) | PE20070691A1 (pt) |
PL (2) | PL2191824T3 (pt) |
PT (2) | PT1898904E (pt) |
RU (1) | RU2423124C2 (pt) |
SA (1) | SA06270171B1 (pt) |
SI (1) | SI1898904T1 (pt) |
TN (1) | TNSN07464A1 (pt) |
TW (1) | TWI381835B (pt) |
WO (1) | WO2006135723A2 (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2434870C2 (ru) * | 2003-11-17 | 2011-11-27 | Мерк Эпрова Аг | Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина |
ATE537141T1 (de) | 2004-02-05 | 2011-12-15 | Kyorin Seiyaku Kk | Bicycloesterderivat |
JP2008501657A (ja) * | 2004-06-02 | 2008-01-24 | サンド・アクチエンゲゼルシヤフト | 結晶形態のメロペネム中間体 |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
JP5305909B2 (ja) * | 2005-09-21 | 2013-10-02 | フォーエスシー アクチエンゲゼルシャフト | ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩 |
EA201001799A1 (ru) * | 2005-10-31 | 2011-06-30 | Янссен Фармацевтика Н.В. | Новые способы получения пиперазинильных и диазепанильных производных бензамида |
CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
CA2645154C (en) | 2006-03-08 | 2011-11-29 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
WO2007144006A1 (en) * | 2006-06-16 | 2007-12-21 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
EP2076516B1 (en) * | 2006-10-27 | 2013-12-11 | Signal Pharmaceuticals LLC | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
CN102119139A (zh) | 2008-08-07 | 2011-07-06 | 杏林制药株式会社 | 二环[2.2.2]辛胺衍生物的制造方法 |
JP5906086B2 (ja) | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fab関連疾患の治療に用いるためのプリン誘導体 |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
CN106177958A (zh) | 2009-02-13 | 2016-12-07 | 勃林格殷格翰国际有限公司 | 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
SG174504A1 (en) * | 2009-03-27 | 2011-10-28 | Bristol Myers Squibb Co | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
CA2756428A1 (en) * | 2009-03-27 | 2010-09-30 | Mamoru Fukuda | Matrix-type sustained release preparation containing basic additive |
US20120201885A1 (en) * | 2009-10-23 | 2012-08-09 | Merck Sharp & Dohme Corp | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
US8343970B2 (en) | 2010-03-12 | 2013-01-01 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
CN103189360A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
TR201101809A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
TR201010683A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
EP2468268B1 (en) | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
TR201107482A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
EP2572704A1 (en) | 2011-09-22 | 2013-03-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-Disintegrating Formulations of Vildagliptin |
EP2760859A1 (en) * | 2011-09-30 | 2014-08-06 | Sunshine Lake Pharma Co., Ltd | Crystalline forms of azilsartan and preparation and uses thereof |
EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JP6283316B2 (ja) * | 2012-10-26 | 2018-02-21 | 株式会社三和化学研究所 | アナグリプチン含有固形製剤 |
US20170014380A1 (en) | 2014-03-06 | 2017-01-19 | Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptin Formulation Process Under Inert Gas Atmosphere |
NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
RU2585378C1 (ru) * | 2014-11-28 | 2016-05-27 | Дмитрий Сергеевич Титов | Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию вилдаглиптина и гликвидона |
EP3285760A4 (en) | 2015-04-24 | 2018-09-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
RU2602688C1 (ru) * | 2015-06-29 | 2016-11-20 | Елена Николаевна Якушева | Способ моделирования состояния ингибирования функциональной активности гликопротеина-р ингибитором дипептидилпептидазы 4 |
JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Pde10阻害剤の固体状態形態 |
KR20180092981A (ko) * | 2015-12-28 | 2018-08-20 | 욱크하르트 리미티드 | 빌다글립틴의 경구 삼투압성 약제학적 조성물 |
WO2018050892A1 (en) * | 2016-09-16 | 2018-03-22 | Galenicum Health S.L. | Vildagliptin pharmaceutical compositions |
WO2020240594A1 (en) * | 2019-05-29 | 2020-12-03 | Abbott Healthcare Pvt. Ltd. | A pharmaceutical composition for diabetes mellitus |
JP7461735B2 (ja) * | 2019-12-02 | 2024-04-04 | 日本ジェネリック株式会社 | ビルダグリプチン含有錠剤 |
CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
WO2021234430A1 (en) * | 2020-05-17 | 2021-11-25 | Lotus International Pte. Ltd. | Modified release dosage form comprising vildagliptin and process for manufacturing the same |
CN115054582B (zh) * | 2022-08-08 | 2022-12-06 | 北京惠之衡生物科技有限公司 | 一种维格列汀片的制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
AU766831B2 (en) | 1998-05-11 | 2003-10-23 | Takeda Pharmaceutical Company Limited | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
EP1140084A1 (en) * | 1998-12-22 | 2001-10-10 | Novo Nordisk A/S | Novel formulation |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
DE60124861T2 (de) * | 2000-01-21 | 2007-05-10 | Novartis Ag | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
JP2003528135A (ja) | 2000-03-31 | 2003-09-24 | プロバイオドラッグ アーゲー | 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法 |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
EP1323710B1 (en) | 2000-10-06 | 2008-09-10 | Mitsubishi Tanabe Pharma Corporation | Nitrogenous five-membered ring compounds |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
CA2433090A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
IL157179A0 (en) | 2001-02-02 | 2004-02-08 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
KR100926247B1 (ko) | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2005500308A (ja) | 2001-06-20 | 2005-01-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤 |
ATE381539T1 (de) | 2001-06-20 | 2008-01-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
DE60222667T2 (de) | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
WO2003024942A1 (fr) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
JP2005509603A (ja) | 2001-09-19 | 2005-04-14 | ノボ ノルディスク アクティーゼルスカブ | Dpp−iv酵素の阻害剤であるヘテロ環化合物 |
GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
JP5105684B2 (ja) * | 2002-03-15 | 2012-12-26 | 大塚製薬株式会社 | 持続性医薬製剤 |
JP2004123738A (ja) * | 2002-09-11 | 2004-04-22 | Takeda Chem Ind Ltd | 徐放性製剤 |
WO2004024184A1 (ja) | 2002-09-11 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 徐放性製剤 |
DK1556362T3 (da) | 2002-10-18 | 2008-06-09 | Merck & Co Inc | Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes |
US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
WO2004082665A1 (ja) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
EP1782832A4 (en) * | 2004-08-26 | 2009-08-26 | Takeda Pharmaceutical | MEANS FOR THE TREATMENT OF DIABETES |
WO2006047248A1 (en) * | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
-
2006
- 2006-06-01 MY MYPI20062526 patent/MY152185A/en unknown
- 2006-06-06 JO JO2006163A patent/JO2584B1/en active
- 2006-06-07 GT GT200600246A patent/GT200600246A/es unknown
- 2006-06-08 NZ NZ563447A patent/NZ563447A/en not_active IP Right Cessation
- 2006-06-08 KR KR1020077028585A patent/KR101312812B1/ko active IP Right Grant
- 2006-06-08 DE DE602006009656T patent/DE602006009656D1/de active Active
- 2006-06-08 AT AT09172285T patent/ATE549019T1/de active
- 2006-06-08 ES ES06772653T patent/ES2334261T3/es active Active
- 2006-06-08 AR ARP060102393A patent/AR054383A1/es unknown
- 2006-06-08 PT PT06772653T patent/PT1898904E/pt unknown
- 2006-06-08 WO PCT/US2006/022416 patent/WO2006135723A2/en active Application Filing
- 2006-06-08 AU AU2006257947A patent/AU2006257947B2/en not_active Ceased
- 2006-06-08 ES ES09172285T patent/ES2385129T3/es active Active
- 2006-06-08 DK DK06772653T patent/DK1898904T3/da active
- 2006-06-08 EP EP06772653A patent/EP1898904B1/en active Active
- 2006-06-08 PT PT09172285T patent/PT2191824E/pt unknown
- 2006-06-08 AT AT06772653T patent/ATE444748T1/de active
- 2006-06-08 PL PL09172285T patent/PL2191824T3/pl unknown
- 2006-06-08 SI SI200630500T patent/SI1898904T1/sl unknown
- 2006-06-08 RU RU2007148241/15A patent/RU2423124C2/ru active
- 2006-06-08 US US11/916,931 patent/US20100021539A1/en not_active Abandoned
- 2006-06-08 BR BRPI0613499A patent/BRPI0613499B8/pt active IP Right Grant
- 2006-06-08 PL PL06772653T patent/PL1898904T3/pl unknown
- 2006-06-08 MX MX2007015677A patent/MX2007015677A/es active IP Right Grant
- 2006-06-08 EP EP09172285A patent/EP2191824B1/en active Active
- 2006-06-08 CA CA002610422A patent/CA2610422A1/en not_active Abandoned
- 2006-06-08 JP JP2008515955A patent/JP5579986B2/ja active Active
- 2006-06-09 PE PE2006000647A patent/PE20070691A1/es active IP Right Grant
- 2006-06-09 TW TW095120638A patent/TWI381835B/zh not_active IP Right Cessation
- 2006-06-09 PE PE2015000134A patent/PE20150728A1/es not_active Application Discontinuation
- 2006-06-09 PE PE2010001149A patent/PE20110057A1/es not_active Application Discontinuation
- 2006-06-10 SA SA6270171A patent/SA06270171B1/ar unknown
-
2007
- 2007-11-15 IL IL187420A patent/IL187420A/en active IP Right Grant
- 2007-12-07 TN TNP2007000464A patent/TNSN07464A1/en unknown
- 2007-12-07 EC EC2007007987A patent/ECSP077987A/es unknown
- 2007-12-26 MA MA30508A patent/MA29564B1/fr unknown
-
2008
- 2008-01-10 NO NO20080177A patent/NO343043B1/no not_active IP Right Cessation
- 2008-06-26 HK HK08107114.8A patent/HK1117037A1/xx not_active IP Right Cessation
-
2009
- 2009-12-21 HR HR20090680T patent/HRP20090680T1/hr unknown
-
2010
- 2010-01-05 CY CY20101100020T patent/CY1109719T1/el unknown
- 2010-10-15 HK HK10109778.7A patent/HK1143094A1/xx not_active IP Right Cessation
- 2010-12-15 US US12/968,885 patent/US20110086096A1/en not_active Abandoned
-
2013
- 2013-05-24 JP JP2013110179A patent/JP2013177428A/ja not_active Withdrawn
-
2015
- 2015-01-15 JP JP2015006061A patent/JP2015091864A/ja not_active Withdrawn
-
2016
- 2016-06-15 JP JP2016119018A patent/JP2016222675A/ja not_active Withdrawn
-
2018
- 2018-06-04 JP JP2018106602A patent/JP2018172392A/ja not_active Withdrawn
-
2019
- 2019-11-13 JP JP2019205708A patent/JP2020055816A/ja not_active Withdrawn
-
2022
- 2022-01-27 JP JP2022010646A patent/JP2022058771A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1117037A1 (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)- carbonitrile formulation | |
ZA200710192B (en) | Substituted arylpyrazoles for use against parasitites | |
ZA200707250B (en) | Extended release formulation of levetiracetam | |
EP1731882A4 (en) | STRUCTURE FOR AGENT CONTAINER R DUTOR | |
IL191287A0 (en) | Atorvastatin formulation | |
ZA200802602B (en) | Controlled release formulation | |
GB0526419D0 (en) | Formulation | |
IL183594A0 (en) | Phenyl-piperazin methanone derivatives | |
GB0517673D0 (en) | Formulation | |
GB0516481D0 (en) | Trailers | |
IL184847A0 (en) | Pharmaceutical composition comprising an indolylmaleimide derivative | |
GB0423565D0 (en) | Formulation | |
GB0624565D0 (en) | Veterinary composition | |
GB0518129D0 (en) | Ramipril formulation | |
ZA200709499B (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile formulation | |
GB0508991D0 (en) | Veterinary composition | |
GB0501030D0 (en) | Formulation | |
PL1928232T3 (pl) | Stała formulacja | |
GB0426661D0 (en) | Pyrrolidine compounds | |
SG123660A1 (en) | Spanner | |
HU0400305D0 (en) | Set for spine-fixture | |
ZA200703442B (en) | Proline derivatives | |
GB0414083D0 (en) | Horsebox loading bar | |
GB0521529D0 (en) | Ramipril formulation | |
GB0401114D0 (en) | Formulation |